Background – Opportunities by introducing Pharmaceutical Product in HK
With increasing interaction between Hong Kong and China’s healthcare industries, Hong Kong has received support from both the Central Government of China and the Hong Kong Government in promoting its healthcare services within the mainland China market, and in particular within the Greater Bay Area.
In November 2019, the Central Government of China further announced that Hong Kong-registered drugs and common medical devices can now be used at designated healthcare institutions established in the Greater Bay Area by Hong Kong healthcare service providers.
The new measures provide a great opportunity to pharmaceutical product and device manufacturers all over the world. Many products already registered – or which will be registered in the future – in Hong Kong may be able to enter the mainland China market as a test without going through the existing complicated and lengthy drug registration process. It comes therefore as no surprise that we are witnessing an increasing number of applications for pharmaceutical-related registrations, licences and permits in Hong Kong at this time.